Article ; Online: Avelumab in the Treatment of Advanced Merkel Cell Carcinoma: A Systematic Review.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.
2024 Volume 50, Issue 5, Page(s) 407–411
Abstract: Background: Avelumab, a programmed death ligand-1 inhibitor, has shown success in providing durable responses for difficult-to-treat Merkel cell carcinomas (MCCs).: Objective: Evaluate the efficacy and safety of avelumab in the treatment of advanced ... ...
Abstract | Background: Avelumab, a programmed death ligand-1 inhibitor, has shown success in providing durable responses for difficult-to-treat Merkel cell carcinomas (MCCs). Objective: Evaluate the efficacy and safety of avelumab in the treatment of advanced MCC. Methods: Studies reporting the use of avelumab as a monotherapy or in combination with other agents in the treatment of stage III or IV (advanced) MCC were included. The primary outcomes were overall response rate, overall survival (OS), and treatment-related adverse events. Results: A total of 48 studies were included, involving 1,565 patients with advanced MCC. Most patients were male (1,051, 67.3%) with stage IV MCC (517, 97.0%). The overall response rate was 46.1% (partial response-25.4% and complete response-20.7%) after a mean follow-up period of 9.5 months. Kaplan-Meier survival curves for the pooled stage III and IV group demonstrated OS rates of 58% at 1 year, 47% at 2 years, and 28% at 5 years after completion of treatment with avelumab (median OS: 23.1 months). The most common treatment-related adverse events consisted of constitutional (44%), gastrointestinal (19%), and dermatologic (12%) symptoms. Conclusion: Avelumab monotherapy and combination therapy have shown success in the overall response rate and survival for patients with advanced MCC. |
---|---|
MeSH term(s) | Carcinoma, Merkel Cell/drug therapy ; Carcinoma, Merkel Cell/pathology ; Humans ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology ; Skin Neoplasms/mortality ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/administration & dosage ; Neoplasm Staging ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Treatment Outcome ; Survival Rate |
Chemical Substances | avelumab (KXG2PJ551I) ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological |
Language | English |
Publishing date | 2024-02-13 |
Publishing country | United States |
Document type | Systematic Review ; Journal Article |
ZDB-ID | 1227586-4 |
ISSN | 1524-4725 ; 1076-0512 |
ISSN (online) | 1524-4725 |
ISSN | 1076-0512 |
DOI | 10.1097/DSS.0000000000004107 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1212: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.